Triple immunotherapy cocktail aims to boost surgery success in liver cancer
NCT ID NCT07714317
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This phase Ib/II trial investigates whether combining three drugs—two immunotherapies (IBI310 and sintilimab) and a blood-vessel blocker (bevacizumab)—given before and after surgery can improve outcomes for people with resectable hepatocellular carcinoma (liver cancer). The study enrolls adults aged 18–75 with a single tumor larger than 5 cm or 2–3 tumors of any size, without major blood vessel involvement or spread. The main goal is to measure how much tumor tissue dies after the pre-surgery treatment, with follow-up on recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of three drugs: IBI310 (anti-CTLA-4), sintilimab (anti-PD-1), and bevacizumab (anti-VEGF)
- What this could lead to
- If successful, this approach could improve the chances of removing all cancer during surgery and reduce the risk of recurrence in people with resectable liver cancer.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination of multiple immune drugs can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Drug cocktail aims to stop liver cancer recurrence after surgery
- New blood test aims to catch liver cancer recurrence early
- New drug combo shows promise in shrinking liver tumors before surgery
- New drug combo aims to shrink liver tumors before surgery
- New combo therapy aims to boost liver cancer surgery success
- Liver cancer patients get Pre-Surgery combo: radiation plus immunotherapy shows promise